Baxter International, Inc.

  • Look to This Medical Equipment Leader For Consistent Growth

    By Matthew Frankel - August 17, 2013 | Tickers: BAX, BDX, MDT

    The health care sector can be daunting for some investors, and there are some good reasons for why many people won’t go near health care stocks. First, the health care laws have been changing constantly (how many times has Obamacare been changed?) and it is hard to say with any degree of certainty how the changing laws will affect these companies’ bottom lines. Also, when a lot of people more »

  • Two Medical Equipment Companies to Own and One to Sell

    By Phillip Woolgar - August 13, 2013 | Tickers: BAX, BSX, MDT

    Most investors agree that the economy is recovering nicely, as evidenced by a 7.4% unemployment rate, down after hitting highs of over 10% in 2009. This means a major turnaround for earnings at a number of companies. The story is even brighter for medical equipment firms, which also look to capitalize on other factors.

    Investors in medical equipment companies should be excited about the massive number of babies born more »

  • This Healthcare Company Is Poised for Growth

    By Nick Chiu - August 9, 2013 | Tickers: BAX, BIIB, HALO

    The performance of Baxter International (NYSE: BAX), the world’s second-largest maker of dialysis products, has been lagging the market with 7.38% gain YTD as of Aug 2, 2013 compared to the 21.91% increase of the S&P 500. However, Baxter is in a transition year as it begins to digests its recent acquisition, Gambro, while preparing for some major new product launches.

    Approved acquisition

    In July, Baxter more »

  • How to Profit From Obesity

    By Ted Cooper - August 8, 2013 | Tickers: BAX, DVA, FMS

    Obesity rates are soaring in the United States. According to the American Heart Association, 155 million adults and 24 million children are overweight or obese. Type 2 diabetes is being diagnosed at record rates. Some 61% of overweight children have at least one risk factor for heart disease. And fewer than 25% of Americans eat a healthy diet and exercise regularly.

    As the unemployment rate rises and fast food becomes more »

  • Who Stands to Lose the Most From This Biotech Breakup?

    By Leo Sun - August 2, 2013 | Tickers: BAX, HALO, PFE, RHHBY, VPHM

    Shares of ViroPharma (NASDAQ: VPHM) and Halozyme Therapeutics (NASDAQ: HALO) dropped in tandem on August 1, after ViroPharma discontinued a Phase II study of administering its flagship drug, Cinryze, subcutaneously with Halozyme’s recombinant human enzyme technology. ViroPharma shares declined nearly 7% after the announcement, but Halozyme plunged almost 14%, due to ViroPharma’s statement that it would pursue similar studies for subcutaneous injection by using other products, which raised more »

  • 3 Dividend Stock Picks for Your Portfolio

    By Adem Tahiri - July 31, 2013 | Tickers: BAX, DEO, GIS

    This market presents a ripe environment for dividend paying stocks. With rising interest rates hurting bond valuations, dividends provide income that makes more sense than ever. If you feel the market is due for a correction, from its current record levels, dividend payers may also provide some of the safety you seek.

    But not all dividend payers are created equal. We want dividend stocks that can increase their payment, so more »

  • Following the Blood Trail to Three Worthy Healthcare Investments

    By Leo Sun - July 31, 2013 | Tickers: BAX, CERS, HAE

    Blood collecting, testing, and treatments are key components of the healthcare system. Therefore, can healthcare investors follow a blood trail across several blood-related companies to unveil some interesting investment opportunities?

    In this article, I’ll take a look at blood collection device maker Haemonetics (NYSE: HAE), blood safety system company Cerus Corporation (NASDAQ: CERS), and diversified medical supply maker Baxter International (NYSE: BAX), which has a large department focused on more »

  • This Healthcare Stock Can Continue Its Rally

    By Piyush Arora - July 29, 2013 | Tickers: BAX, BDX, STJ

    Thanks to an expanding product portfolio, increasing healthcare spending, and explosive growth in the emerging markets, the healthcare industry has been growing at a stellar rate lately. Medical supplies and equipment providers are benefiting the most, as they serve the global healthcare industry. One of the most prominent beneficiaries has been Becton Dickinson (NYSE: BDX), which has recorded an appreciation of 45% over the last year. But, despite the recent more »

  • Should You Buy These 2 Medical Device Stocks?

    By David Gould - July 23, 2013 | Tickers: BAX, BIIB, MDT

    Medical device stocks are an excellent place to be if you are still wary of the macro-economy. They are exposed to inelastic demand and don't have pipelines full of "hit-or-miss" products. Their business models are relatively time-tested, and they often pay a good dividend yield. Below, I review two market leaders and provide my thoughts on recent news about them.

    Baxter (NYSE: BAX) still looks attractive

    Baxter International, the more »

  • Is This Delivery-Focused Biotech a Buy?

    By Sherrie Stone - July 22, 2013 | Tickers: BAX, HALO, RHHBY

    Editor’s Note: A previous version of this article referred to rHuPH20 as Hylenex.

    Halozyme Therapeutics (NASDAQ: HALO) moved higher by 25% on Friday behind the news of a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Roche’s Herceptin SC for European approval. This almost certainly signals an EU approval for Herceptin SC, and this is tremendous news for Halozyme more »

  • Is This Gloomy Warning a Telltale Sign for the Medical Devices Industry?

    By Ryan Guenette - July 17, 2013 | Tickers: BAX, BDX, ISRG, MDT

    On July 9, Intuitive Surgical (NASDAQ: ISRG) warned of second-quarter financial results coming in at disappointing levels, although the company does not officially report until July 18.

    The company stated that it expects sales to come in at $575 million for the second quarter, nearly 9% south of the consensus of Wall Street analysts. Year over year, growth is still anticipated to top 7%; however, it will be the first more »

  • 3 Medical Instrument and Supply Companies You Don’t Want to Miss

    By Shweta Dubey - July 10, 2013 | Tickers: BAX, BDX, COV

    The U.S. is the world’s leading medical device manufacture. Becton Dickinson (NYSE: BDX), Baxter International (NYSE: BAX), Covidien (NYSE: COV) are amongst the top ten manufactures for medical devices. The U.S. medical device industry is expected to grow at CAGR 6.3% for the period of 2011-2018. The medical device market revenue is projected to increase from $102.1 billion in 2011 to $156.8 billion by more »

  • This Biotechnology Stock Is On The Roll

    By Kanak Kanti - July 10, 2013 | Tickers: BAX, BIIB, PFE

    Biogen Idec (NASDAQ: BIIB) is in the news again; on July 4, 2013 the company presented new data in support of clinical and safety profile for ELOCTATE, its candidate for hemophilia A that it is developing in partnership with Swedish Orphan Biovitrum AB. Earlier, in May this year, the FDA had accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE. Biogen now has product candidates more »

  • 3 Companies That May Help You Living Longer

    By Damian Illia - July 5, 2013 | Tickers: BAX, COV, RMD

    An aging western society has opened many opportunities for firms involved in pharmaceuticals, medical instruments and supplies. The following three: ResMed (NYSE: RMD), Covidien (NYSE: COV), and Baxter International (NYSE: BAX) have created a small economic moats for themselves, are fair valued, and hold positive future outlooks. Let us find why, despite their troubled present, their futures may be brighter.

    Already dreaming more profits

    Focused on sleep disorders, medical instruments more »

  • One Pharma Stock Investors Should Watch

    By Rashmi Singh - July 1, 2013 | Tickers: BAX, FMS, GRFS

    Baxter International (NYSE: BAX), one of the fastest-growing healthcare multinational corporations of America, has a long history of strong financial credentials. With a single-point agenda of emerging out as a clear leader in its core area of operations, Baxter has repeatedly proven its might.

    The FY 2012 growth story

    With FY 2012, the company wrapped up another successful business year. It achieved 5 % year-over-year growth in revenue (exclusive of foreign more »

  • Can This Small Pharma Company’s Investors Breathe Easy?

    By Arturo Cuevas - June 29, 2013 | Tickers: BAX, GRFS, KMDA

    Investors have reasons to be wary about small-cap biotech companies, particularly those ambitious start-ups which have been sprouting like mushrooms in the market this year. Many coming into the fray are companies which have yet to gain authorities’ approval for any of the drugs they are developing and thus are generally high-risk.

    There’s one recent market debut, though, where the trepidation seems lower — Kamada (NASDAQ: KMDA). This June, this more »

  • Three Solid Long-Term Pharma Picks

    By Vikas Shukla - June 27, 2013 | Tickers: BAX, LLY, PFE

    A recession hampers almost every economic activity, but it does not reduce health problems. That’s why pharma products are always in demand.

    Moreover, there is a rising demand for good healthcare in developing countries in the Asia-Pacific region. The increasing population of retirees in developed countries will further ensure that the pharmaceutical industry maintains its robust growth. Investing in the pharma sector makes sense, right?

    However, a big problem more »

  • Michael Price Is Bullish on This Drug Manufacturer

    By Anh HOANG - June 24, 2013 | Tickers: BAX, BDX, HSP

    Editor's Note:The initial article stated Hospira closed their largest plant due to FDA actions. This is incorrect; Hospira shut their plant for scheduled maintenance. This version has been corrected and Motley Fool apologizes for the error.

    At the London Value Investor Conference, famous value investor Michael Price pitched Hospira (NYSE: HSP) as one of his favorite stocks. As of March, Price owned 400,000 Hospira shares. Hospira seems more »

  • Can't Anyone Tackle Alzheimer's?

    By Kanak Kanti - June 24, 2013 | Tickers: BAX, BMY, LLY, MRK, PFE

    After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly (NYSE: LLY), really has a foolproof plan to develop a useful treatment for Alzheimer’s. Although the companies discussed below are all great businesses, don't base your investment decisions on their Alzheimer's pipelines.

    Secretase inhibitors in very simple terms

    The science behind this approach to more »

  • Don’t Believe the Hype about Medical Device Stocks

    By Jonathan Yates - June 9, 2013 | Tickers: BAX, BDX, BSX

    A major loser in the Affordable Health Care Act, or Obamacare, was supposed to be the medical device and equipment industry, which ranges from blue chip heavyweights with wide product offerings such as Boston Scientific (NYSE: BSX), Becton,Dickinson & Co. (NYSE: BDX), and Baxter International (NYSE: BAX) to specialized small caps such as PLC Systems (NASDAQ: PLCSF). The main feature of Obamacare that was expected to damage the sector the more »

  • Page 1 of 4